Announcements Trials
Browse Landscape

Phase

Phase NA 14Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 17Gastrointestinal 13Thoracic 11Breast 11Head & Neck 9Other hematologic neoplasm 7CNS 6Gynecologic 5Lymphoid 4Tumor-Agnostic 3Dermatologic 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Endocrine 1

Conditions

Oligometastatic Malignant Solid Neoplasm 1

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Standard of Care × Other solid neoplasm × Clear all
NCT03599765 2025-12-31

Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
380 enrolled
Other solid neoplasm

Oligometastatic Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡